Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | F9 | P00740 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9863137 | 0.89 | PPARA (0.67) | PPARAPPARGHPGDALDH1A1GAA | |
| SCHEMBL11828515 | 0.85 | PPARA (0.63) | PPARAPPARGHPGDALDH1A1GAA | |
| SCHEMBL6494581 | 0.84 | GAA (0.66) | PPARAPPARGHPGDMEN1ALDH1A1 | |
| SCHEMBL1432111 | 0.84 | KMT2A (0.58) | HPGDMEN1ALDH1A1KMT2AGAA | |
| SCHEMBL853578 | 0.84 | CYSLTR2 (0.56) | PPARAPPARGALDH1A1NPC1 | |
| SCHEMBL25226906 | 0.83 | GAA (0.53) | PPARAPPARGHPGDMEN1ALDH1A1 | |
| SCHEMBL2317973 | 0.83 | LMNA (0.66) | PPARAPPARGHPGDMEN1ALDH1A1 | |
| SCHEMBL2557974 | 0.82 | PPARA (0.56) | PPARAPPARGHPGDMEN1ALDH1A1 | |
| SCHEMBL6463823 | 0.81 | PPARA (0.59) | PPARAPPARGHPGDGAAKDM4E | |
| SCHEMBL7033340 | 0.81 | PPARA (0.59) | PPARAPPARGHPGDALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855260-B2 | Quinolinone derivatives | GLAXOSMITHKLINE LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-20150238480-A1 | QUINOLINONE DERIVATIVES | GLAXOSMITHKLINE LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150238480-A1 | QUINOLINONE DERIVATIVES | GLAXOSMITHKLINE LLC | 2015-08-27 | — | — | US | disclosed |
| US-9061998-B2 | Quinolinone derivatives | GLAXOSMITHKLINE LLC (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061998-B2 | Quinolinone derivatives | GLAXOSMITHKLINE LLC (US) | 2015-06-23 | — | — | US | disclosed |
| WO-2012119978-A1 | QUINOLINONE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2012-09-13 | — | — | WO | disclosed |
| US-8217027-B2 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217027-B2 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217027-B2 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-03 | — | — | US | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1051176-A4 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARM PROD INC (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| CN-1291892-A | Substituted oxoazaheterocyclyl factor Xa inhibitors | AWENTIS PHARMACEUTICAL INC (US) | 2001-04-18 | — | — | CN | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000032590-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| US-3985791-A | 16-Phenoxy and 16-substituted phenoxy-prostatrienoic acid derivatives | SYNTEX (U.S.A.) INC. (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238480-A1 | QUINOLINONE DERIVATIVES | PRKAG2, PRKAB2, PRKAG1 | PPARA 110/4885PPARG 30/4885HPGD 621/4885 |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | PPARA 4605/4885PPARG 4588/4885HPGD 547/4885 |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | P2RX3, P2RX2, P2RX5 | PPARA 3104/4885PPARG 2636/4885HPGD 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.